Invasive squamous cell carcinoma of the cervix

Cervical invasive squamous cell carcinoma is the most common pathological type of cervical cancer. It is a malignant tumor and requires comprehensive treatment such as surgery, radiotherapy, and chemotherapy. There may be no obvious symptoms in the early stage, but abnormal vaginal bleeding, discharge or pain may occur in the advanced stage. It is recommended that patients seek medical treatment promptly and have a specialist develop an individualized treatment plan.

1. Causes and high-risk factors

Cervical invasive squamous cell carcinoma is mainly associated with human papillomavirus infection, especially high-risk HPV16 and HPV18. Other risk factors include multiparity, long-term oral contraceptive use, immunosuppressed status, and smoking. Genetic factors may influence an individual's ability to clear HPV. Early screening and HPV vaccination are important prevention methods.

2.Clinical manifestations

The disease is often asymptomatic in the early stages, and some patients develop contact vaginal bleeding or abnormal discharge. Progressive stages may present with irregular vaginal bleeding, foul-smelling discharge, pelvic pain, or difficulty urinating. Systemic symptoms such as weight loss and anemia may occur in the late stages. The appearance of symptoms often indicates that the tumor has broken through the basement membrane and infiltrated.

3. Diagnostic methods

Diagnosis requires a combination of cervical cytology, HPV testing and colposcopy biopsy. Imaging examinations such as MRI can evaluate the extent of local invasion, and PET-CT can help detect distant metastasis. Pathological diagnosis requires observation of cancer cells breaking through the basement membrane and infiltrating into the interstitium. A depth exceeding 3 mm is considered invasive cancer.

4. Treatment principles

The treatment plan is selected according to the stage. Radical hysterectomy is feasible in the early stage, and concurrent radiotherapy and chemotherapy are required in the middle and late stage. Cervical conization or radical trachelectomy can be performed to preserve fertility. Targeted drugs such as bevacizumab can be used in recurrent or metastatic cases. The treatment plan needs to be developed by the gynecological oncology team.

5. Prognosis and follow-up

The five-year survival rate is closely related to the stage, and can reach more than 80% in stage I. Regular follow-up is required after treatment, including gynecological examination, tumor marker and imaging evaluation. Lifestyle modifications include quitting smoking, eating a balanced diet, and exercising moderately. Psychological support is particularly important to improve quality of life.

After diagnosis, a standardized follow-up plan should be established and reexamined every 3-6 months. Keep the perineum clean and avoid strenuous exercise that may cause bleeding. The diet needs to ensure the intake of high-quality protein and vitamins, such as fish, eggs and dark vegetables. Perform appropriate pelvic floor muscle exercises to avoid long-term bed rest. If you experience abnormal bleeding or pain, seek medical attention immediately. During treatment, you can seek professional psychological counseling to help deal with anxiety.